Fabio Calabro'

Aug 16, 2023 | frontiersin.org | Sun Young |South Brisbane |Umang Swami |Fabio Calabro'

1 IntroductionKidney cancer is one of the most frequently diagnosed cancers in the United States, and the activity of traditional cytotoxic chemotherapy is limited in patients with metastatic renal cell carcinoma (RCC) (1). The phase 3 multicenter, open-label, randomized, CLEAR study (Study 307/KEYNOTE-581) compared the efficacy and safety of lenvatinib plus pembrolizumab or everolimus versus sunitinib as a first-line treatment for patients with advanced RCC (2).